Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment.

JACC. Asia·2026
Same author

Pharmacological management of elevated LDL in patients with hypercholesterolemia and mixed dyslipidaemia.

Expert opinion on pharmacotherapy·2026
Same author

Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China.

EClinicalMedicine·2026
Same author

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.

The New England journal of medicine·2025
Same author

Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same journal

Lack of Association Between Sodium Intake and Cytokine Levels.

Integrated blood pressure control·2024
Same journal

Prevalence and Predictors of Depression Symptoms Among Afghan Hypertensive Patients: Secondary Analysis of a Multi-Center Cross-Sectional Study.

Integrated blood pressure control·2024
Same journal

Prevalence of Risk Factors for Hypertension Among Faculty at an Urban University in Uganda [Response to Letter].

Integrated blood pressure control·2024
Same journal

Resistance Training in Cardiovascular Diseases: A Review on Its Effectiveness in Controlling Risk Factors.

Integrated blood pressure control·2024
Same journal

Thoughts on "Prevalence of Risk Factors for Hypertension Among Faculty at an Urban University in Uganda" [Letter].

Integrated blood pressure control·2024
Same journal

Adherence to Lifestyle Modification Practices and Its Associated Factors Among Hypertensive Patients in Bahir Dar City Hospitals, North West Ethiopia [Letter].

Integrated blood pressure control·2024
See all related articles

Related Experiment Video

Updated: May 11, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Current Perspectives on rosuvastatin.

Miao Hu1, Brian Tomlinson

  • 1Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong.

Integrated Blood Pressure Control
|May 3, 2013
PubMed
Summary
This summary is machine-generated.

Rosuvastatin effectively lowers low-density lipoprotein cholesterol (LDL-C), reducing cardiovascular events and slowing atherosclerosis progression. While generally safe, its benefits outweigh risks for most high-risk patients, despite a slight increase in diabetes risk.

Keywords:
atherosclerosiscardiovascular diseaselipidsrosuvastatin

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: May 11, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Rosuvastatin is a potent statin for lowering low-density lipoprotein cholesterol (LDL-C).
  • Its pleiotropic effects include anti-inflammatory and antioxidant properties, improving endothelial function.
  • These actions slow atherosclerosis progression and benefit cardiovascular outcomes.

Purpose of the Study:

  • To review recent large clinical trials on rosuvastatin's safety and efficacy.
  • To update understanding of rosuvastatin's role in managing cardiovascular risk.

Main Methods:

  • Review of recent large-scale clinical trials.
  • Analysis of rosuvastatin's effects across various patient populations and risk levels.

Main Results:

  • Rosuvastatin demonstrates efficacy in slowing atherosclerosis progression across its dosage range (2.5-40 mg).
  • It reduced cardiovascular events in lower-risk individuals with elevated hs-CRP and normal LDL-C.
  • No survival benefit was observed in heart failure patients; no cardiovascular event reduction in ESRD patients on hemodialysis.

Conclusions:

  • Rosuvastatin is beneficial for cardiovascular risk reduction in hypertensive patients, alongside antihypertensive therapy.
  • Absolute cardiovascular benefits of statin therapy generally outweigh the slight increased risk of diabetes in moderate-to-high risk individuals.
  • Identifying specific patient subgroups may optimize statin therapy benefits, particularly in heart failure.